GlassScriptPhysician profile
Amy Brownell
NPI 1619342326
$201,917.83
in general payments reported to CMS, 2019-2025
23 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,889 · 2022: $32K · 2023: $34K · 2024: $86K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Travel and Lodging: $38K · Food and Beverage: $10K · Consulting Fee: $7,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109,243.00 |
| Travel and Lodging | $37,950.90 |
| Food and Beverage | $10,252.84 |
| Consulting Fee | $7,301.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $114,707.01 | 2021-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $70,487.37 | 2022-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $11,659.38 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $2,731.15 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic, INC. | $920.86 | 2024 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $309.39 | 2023-2025 | Wainua, Farxiga |
| Abbott Laboratories | $159.00 | 2022-2024 | Cardiomems |
| Irhythm Technologies, INC. | $123.53 | 2024 | Zio Xt Patch, Zio Monitor |
| Biosense Webster, INC. | $104.92 | 2025 | Carto 3 |
| Esperion Therapeutics, INC. | $99.65 | 2023-2024 | Nexletol |
| Novo Nordisk INC | $99.49 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.04 | 2021-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $68.32 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $65.14 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.08 | 2023-2024 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.57 | 2023-2025 | |
| Abiomed | $37.54 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $36.36 | 2022-2024 | |
| Pfizer INC. | $33.31 | 2025 | |
| Boston Scientific Corporation | $28.38 | 2025 | Watchman Flx |
| Ucb, INC. | $22.25 | 2025 | Briviact |
| Cvrx, INC. | $22.02 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $21.07 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Brownell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.